Answers are grounded in this paper and cite their sources.
Background: Pulmonary pleomorphic carcinoma is a rare tumor associated with a poor prognosis. In this study, we as-sessed the clinical features of patients with surgically resected pleomorphic carcinoma. Methods: Twenty-eight patients who underwent surgical resection of pulmonary pleomorphic carcinoma between August 2002 and January 2020 were retrospectively analyzed. Results: The patient population consisted of 25 men and 3 women between the ages of 46 and 87 years (median, 73 years), of whom 25 (89%) were smokers. The mean diameter of the tumor was 44.6 mm (range, 17-92 mm). With regard to lymph node metastasis, 22 cases were pN0, 5 were pN1, and one was pN2. The median survival time was 32.0 months, the 5-year overall survival (OS) rate was 39.5%, and the 3-year relapse-free survival (RFS) rate was 31% in all patients. An immunohistochemical study of the resected tumor revealed expression of programmed death-ligand 1 (PD-L1) in 6 patients. An immune checkpoint inhibitor (ICI) was used in all 6 of these cases, and was successful in 5. Conclusion: In this study, the prognosis of patients with pleomorphic carcinoma was poor. No specific prognostic factors were found, but ICI treatment is likely to be effective.
No takes yet. Share an insight, caveat, or question.
Kameda et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: